Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

northstar rxllc - capecitabine (unii: 6804dj8z9u) (capecitabine - unii:6804dj8z9u) - capecitabine 150 mg - - capecitabine tablets, usp are indicated as a single agent for adjuvant treatment in patients with dukes' c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. capecitabine was non-inferior to 5-fluorouracil and leucovorin (5-fu/lv) for disease-free survival (dfs). physicians should consider results of combination chemotherapy trials, which have shown improvement in dfs and os, when prescribing single-agent capecitabine in the adjuvant treatment of dukes' c colon cancer. - capecitabine tablets, usp are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. combination chemotherapy has shown a survival benefit compared to 5-fu/lv alone. a survival benefit over 5-fu/lv has not been demonstrated with capecitabine monotherapy. use of capecitabine tablets, usp instead of 5-fu/lv in combinations has not been adequately studied to assure sa

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

shilpa medicare limited - capecitabine (unii: 6804dj8z9u) (capecitabine - unii:6804dj8z9u) - capecitabine 150 mg - - capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with dukes' c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. capecitabine tablets was non-inferior to 5-fluorouracil and leucovorin (5-fu/lv) for disease-free survival (dfs). physicians should consider results of combination chemotherapy trials, which have shown improvement in dfs and os, when prescribing single-agent capecitabine tablets in the adjuvant treatment of dukes' c colon cancer. - capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. combination chemotherapy has shown a survival benefit compared to 5-fu/lv alone. a survival benefit over 5-fu/lv has not been demonstrated with capecitabine tablets monotherapy. use of capecitabine tablets instead of 5-fu/lv in combinations has not been adequately studied to

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - capecitabine (unii: 6804dj8z9u) (capecitabine - unii:6804dj8z9u) - capecitabine 150 mg - - capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with dukes' c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. capecitabine tablets are non-inferior to 5-fluorouracil and leucovorin (5-fu/lv) for disease-free survival (dfs). physicians should consider results of combination chemotherapy trials, which have shown improvement in dfs and os, when prescribing single-agent capecitabine tablets in the adjuvant treatment of dukes' c colon cancer. - capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. combination chemotherapy has shown a survival benefit compared to 5-fu/lv alone. a survival benefit over 5-fu/lv has not been demonstrated with capecitabine tablets monotherapy. use of capecitabine tablets instead of 5-fu/lv in combinations has not been adequately studied to

Израел - Енглески - Ministry of Health

abic marketing ltd, israel - capecitabine - film coated tablets - capecitabine 150 mg - capecitabine - adjuvant colon cancer: capecitabine teva® is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: capecitabine teva® is indicated for the treatment of patients with advanced or metastatic colorectal cancer. advanced gastric cancer: capecitabine teva® is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy. breast cancer combination therapy: capecitabine teva® in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: capecitabine teva® is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

Израел - Енглески - Ministry of Health

abic marketing ltd, israel - capecitabine - film coated tablets - capecitabine 500 mg - capecitabine - adjuvant colon cancer: capecitabine teva® is indicated for the adjuvant treatment of patients following surgery of stage iii (dukes stage c) colon cancer. colorectal cancer: capecitabine teva® is indicated for the treatment of patients with advanced or metastatic colorectal cancer. advanced gastric cancer: capecitabine teva® is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy. breast cancer combination therapy: capecitabine teva® in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: capecitabine teva® is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

Израел - Енглески - Ministry of Health

taro international ltd, israel - capecitabine - film coated tablets - capecitabine 500 mg - capecitabine - adjuvant colon cancer: capecitabine taro 500mg is indicated for the adjuvant treatment of patients following surgery of stage iii (dukes stage c) colon cancer. colorectal cancer: capecitabine taro 500mg is indicated for the treatment of patients with advanced or metastatic colorectal cancer. advanced gastric cancer: capecitabine taro 500mg is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy. breast cancer combination therapy: capecitabine taro 500mg in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: capecitabine taro 500mg is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

Европска Унија - Енглески - EMA (European Medicines Agency)

accord healthcare s.l.u. - capecitabine - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastic agents - capecitabine accord is indicated for the adjuvant treatment of patients following surgery of stage-iii (dukes’ stage-c) colon cancer.capecitabine accord is indicated for the treatment of metastatic colorectal cancer.capecitabine accord is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.capecitabine accord in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.capecitabine accord is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

Европска Унија - Енглески - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - capecitabine - colorectal neoplasms - antineoplastic agents - capecitabine medac is indicated for the adjuvant treatment of patients following surgery of stage-iii (dukes’ stage-c) colon cancer.capecitabine medac is indicated for the treatment of metastatic colorectal cancer.capecitabine medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.capecitabine medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.capecitabine medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

Европска Унија - Енглески - EMA (European Medicines Agency)

teva pharma b.v. - capecitabine - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastic agents - capecitabine teva is indicated for the adjuvant treatment of patients following surgery of stage iii (dukes’ stage c) colon cancer.capecitabine teva is indicated for the treatment of metastatic colorectal cancer.capecitabine teva is indicated for first‑line treatment of advanced gastric cancer in combination with a platinum‑based regimen.capecitabine teva in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. capecitabine teva is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.